Latest News

Jennifer E. Thorne, MD, PhD, discusses evidence from the ADJUST trial, including relapse risk, retreatment success, and how clinicians should monitor children when considering adalimumab discontinuation.

The company can now initiate its phase 1/2 CLARITY trial activities for its lead in vivo genome-editing program GEB-101 for TGFBI corneal dystrophy.

Joel S. Schuman, MD, FACS, highlights home tonometry, virtual visual fields, and portable OCT devices as promising tools, while noting concerns around data reliability, patient adherence, and reimbursement.

The letter noted the FDA is unable to approve the application for ONS-5010/LYTENAVA (bevacizumab-vikg) in its current form for the treatment of wet AMD, according to the company.

Oluwatosin U. Smith, MD, highlights the practical impact of expanding tools on real-world glaucoma treatment.

Concentric lens positioning of an adjustable lens helps avoid a late myopic shift.

Daniela Ferrara, MD, discusses how data from low- and middle-income countries can strengthen US trials, improve equity, and inform innovation as the field looks toward 2026.

An in-depth look at the FDA approvals and clinical milestones that defined 2025 and how they are poised to influence practice patterns moving into 2026.

The novel system converts light into electrical signals to stimulate retinal cells.

Sahar Bedrood, MD, PhD; Inder Paul Singh, MD; and AnnMarie Hipsley, DPT, PhD, recount moments that blended professional milestones with mentorship and legacy.

Sezen Karakus, MD, highlights options including compounded cyclosporine, autologous serum drops, recombinant human nerve growth factor, and newer topical agents to manage refractory or neurotrophic dry eye.

An overview of the top 10 stories from Optometry Times in 2025.